Get started
Work

Figure 3 from DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer

Year: 2026
Type: other
Abstract: Best percentage change in target lesions from baseline for (A) T-DXd + anastrozole and (B) T-DXd + fulvestrant. 1L, first-line; 2L, second-line; IM, intramuscularly; IV, intravenously; OD, once daily; PO, orally; Q3W, every 3 weeks; Q4W, every 4 weeks; T-DXd, trastuzumab deruxtecan. aT-DXd 5.4 mg/kg IV Q3W + anastrozole 1 mg PO OD. bT-DXd 5.4 mg/kg IV Q3W + fulvestrant 500 mg IM Q4W with 500-mg loading dose on Day 15 of Cycle 1.
DOI: 10.1158/1078-0432.31744725
Authors: Komal Jhaveri, Sherene Loi, Erika Hamilton, Peter Schmid, Carey K. Anders, Laura Testa, Hans Wildiers, Ling-Ming Tseng, Yen-Shen Lu, Yeon Hee Park, Seock-Ah Im, Shin-Cheh Chen, Robyn R. Young, Caron Lloyd, Magdalena Wrona, Cuihong Zhang, Danielle Carroll, Fabrice André
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W7136138259
Cites:
Cited by:
Related to: 10